Progranulin mutations and amyotrophic lateral sclerosis or amyotrophic lateral sclerosis-frontotemporal dementia phenotypes
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Mutations in the progranulin (PGRN) gene were recently described as the cause of ubiquitin positive frontotemporal dementia (FTD). Clinical and pathological overlap between amyotrophic lateral sclerosis (ALS) and FTD prompted us to screen PGRN in patients with ALS and ALS-FTD. METHODS: The PGRN gene was sequenced in 272 cases of sporadic ALS, 40 cases of familial ALS and in 49 patients with ALS-FTD. RESULTS: Missense changes were identified in an ALS-FTD patient (p.S120Y) and in a single case of limb onset sporadic ALS (p.T182M), although the pathogenicity of these variants remains unclear. CONCLUSION: PGRN mutations are not a common cause of ALS phenotypes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17
Baker, M., Mackenzie, I. R., Pickering-Brown, S. M., Gass, J., Rademakers, R., Lindholm, C., Snowden, J., Adamson, J., Sadovnick, A. D., Rollinson, S., et al. (2006) · Nature · doi:10.1038/nature05016 · Cited by 2,058
Self-citationCruts, M., Gijselinck, I., van der Zee, J., Engelborghs, S., Wils, H., Pirici, D., Rademakers, R., Vandenberghe, R., Dermaut, B., Martin, J.-J., et al. (2006) · Nature · doi:10.1038/nature05017 · Cited by 1,512
Self-citationClinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups.
(1994) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.57.4.416 · Cited by 1,331
Ince (1998) · doi:10.1046/j.1365-2990.1998.00108.x · Cited by 224
Cited by
Clinical genetics of amyotrophic lateral sclerosis: what do we really know?
Andersen, P. M., & Al-Chalabi, A. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.150 · Cited by 687
Self-citationStrong, M. J., Grace, G. M., Freedman, M., Lomen-Hoerth, C., Woolley, S., Goldstein, L. H., Murphy, J., Shoesmith, C., Rosenfeld, J., Leigh, P. N., et al. (2009) · Amyotrophic Lateral Sclerosis · doi:10.1080/17482960802654364 · Cited by 546
The role of TDP-43 mislocalization in amyotrophic lateral sclerosis
Suk, T. R., & Rousseaux, M. W. C. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00397-1 · Cited by 450
Van Damme, P., Van Hoecke, A., Lambrechts, D., Vanacker, P., Bogaert, E., van Swieten, J., Carmeliet, P., Van Den Bosch, L., & Robberecht, W. (2008) · The Journal of Cell Biology · doi:10.1083/jcb.200712039 · Cited by 418
Self-citationThe two faces of protein misfolding: gain‐ and loss‐of‐function in neurodegenerative diseases
Winklhofer, K. F., Tatzelt, J., & Haass, C. (2008) · The EMBO Journal · doi:10.1038/sj.emboj.7601930 · Cited by 401
ALS Genetics: Gains, Losses, and Implications for Future Therapies
Kim, G., Gautier, O., Tassoni-Tsuchida, E., Ma, X. R., & Gitler, A. D. (2020) · Neuron · doi:10.1016/j.neuron.2020.08.022 · Cited by 370
Le Ber, I., Camuzat, A., Hannequin, D., Pasquier, F., Guedj, E., Rovelet-Lecrux, A., Hahn-Barma, V., van der Zee, J., Clot, F., Bakchine, S., et al. (2008) · Brain · doi:10.1093/brain/awn012 · Cited by 352
The granulin gene family: from cancer to dementia
Bateman, A., & Bennett, H. P. J. (2009) · BioEssays · doi:10.1002/bies.200900086 · Cited by 337
Genetics of amyotrophic lateral sclerosis: an update
Chen, S., Sayana, P., Zhang, X., & Le, W. (2013) · Molecular Neurodegeneration · doi:10.1186/1750-1326-8-28 · Cited by 326
SQSTM1 mutations in frontotemporal lobar degeneration and amyotrophic lateral sclerosis
Rubino, E., Rainero, I., Chiò, A., Rogaeva, E., Galimberti, D., Fenoglio, P., Grinberg, Y., Isaia, G., Calvo, A., Gentile, S., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e31826e25df · Cited by 286
Self-citationFTD and ALS: A Tale of Two Diseases
Ferrari, R., Kapogiannis, D., D. Huey, E., & Momeni, P. (2011) · Current Alzheimer Research · doi:10.2174/156720511795563700 · Cited by 272
Self-citationvan Swieten, J. C., & Heutink, P. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70194-7 · Cited by 234
The lysosomal function of progranulin, a guardian against neurodegeneration
Paushter, D. H., Du, H., Feng, T., & Hu, F. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1861-8 · Cited by 230
“Accounting for ~ 20–25% of familial FTLD cases and ~ 10% of all FTLD cases, with the majority producing truncated transcripts that are degraded by nonsense-mediated mRNA decay, GRN mutation is primarily associated with the FTLD-TDP subtype and shows minimal connection with ALS [108].”
InfluentialMoisse, K., Volkening, K., Leystra-Lantz, C., Welch, I., Hill, T., & Strong, M. J. (2009) · Brain Research · doi:10.1016/j.brainres.2008.10.021 · Cited by 210
Yu, C.-E., Bird, T. D., Bekris, L. M., Montine, T. J., Leverenz, J. B., Steinbart, E., Galloway, N. M., Feldman, H., Woltjer, R., Miller, C. A., et al. (2010) · Archives of Neurology · doi:10.1001/archneurol.2009.328 · Cited by 190
Progranulin in neurodegenerative disease
Petkau, T. L., & Leavitt, B. R. (2014) · Trends in Neurosciences · doi:10.1016/j.tins.2014.04.003 · Cited by 169
Progranulin genetic variability contributes to amyotrophic lateral sclerosis
Sleegers, K., Brouwers, N., Maurer-Stroh, S., van Es, M. A., Damme, P. V., van Vught, P. W. J., van der Zee, J., Serneels, S., Pooter, T. D., Van den Broeck, M., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000289191.54852.75 · Cited by 161
Self-citationProgranulin: normal function and role in neurodegeneration
Eriksen, J. L., & Mackenzie, I. R. A. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04968.x · Cited by 144
Progranulin: a new avenue towards the understanding and treatment of neurodegenerative disease
Chitramuthu, B. P., Bennett, H. P. J., & Bateman, A. (2017) · Brain · doi:10.1093/brain/awx198 · Cited by 138
“Patients with FTD sometimes develop clinical signs that overlap with motor neuron disease/amyotrophic lateral sclerosis (FTD-ALS), progressive supranuclear palsy and corticobasal syndrome (CBS) associated with Parkinson’s disease while 50% of patients with ALS show cognitive deficits (Lomen-Hoerth et al., 2002; Seltma…”
BackgroundFrontotemporal Lobar Degeneration: Epidemiology, Pathology, Diagnosis and Management
Seltman, R. E., & Matthews, B. R. (2012) · CNS Drugs · doi:10.2165/11640070-000000000-00000 · Cited by 132
Genetic and Clinical Features of Progranulin-Associated Frontotemporal Lobar Degeneration
Chen-Plotkin, A. S., Martinez-Lage, M., Sleiman, P. M. A., Hu, W., Greene, R., Wood, E. M., Bing, S., Grossman, M., Schellenberg, G. D., Hatanpaa, K. J., et al. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.53 · Cited by 120
“Second, motor neuron disease (MND) appears to be rare in FTLD in GRN mutation carriers.(29) Third, some have proposed that GRNassociated FTLD-TDP is more likely to have parkinsonian features than FTLD-TDP without GRN mutations.”
BackgroundSelf-citationMoisse, K., Mepham, J., Volkening, K., Welch, I., Hill, T., & Strong, M. J. (2009) · Brain Research · doi:10.1016/j.brainres.2009.07.023 · Cited by 93
Association of progranulin polymorphism rs5848 with neurodegenerative diseases: a meta-analysis
Chen, Y., Li, S., Su, L., Sheng, J., Lv, W., Chen, G., & Xu, Z. (2015) · Journal of Neurology · doi:10.1007/s00415-014-7630-2 · Cited by 50
“Similarly, the PGRN genetic polymorphism rs5848 has also been demonstrated to increase the risk of AD [6, 7] and the development of PD [16].”
BackgroundKim, E.-J., Vatsavayai, S., & Seeley, W. W. (2016) · The Behavioral Neurology of Dementia · doi:10.1017/9781139924771.008 · Cited by 7
Metadata
- Authors
- Schymick, J. C., Yang, Y., Andersen, P. M., Vonsattel, J. P., Greenway, M., Momeni, P., Elder, J., Chio, A., Restagno, G., Robberecht, W., Dahlberg, C., Mukherjee, O., Goate, A., Graff-Radford, N., Caselli, R. J., Hutton, M., Gass, J., Cannon, A., Rademakers, R., Singleton, A. B., Hardiman, O., Rothstein, J., Hardy, J., & Traynor, B. J.
- Venue
- Journal of Neurology, Neurosurgery & Psychiatry
- Publisher
- BMJ
- Published
- 2006-12-18
- Volume
- 78
- Issue
- 7
- Pages
- 754-756
- ISSN
- 0022-3050 (ISSN-L)
- OpenAlex
- W2099759641
- Cited by
- 134
- References
- 4
- FWCI
- 7.95
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.